Theriva Biologics Inc (TOVX)
1.99
+0.53
(+36.30%)
USD |
NYAM |
Nov 01, 16:00
1.95
-0.04
(-2.01%)
After-Hours: 20:00
Theriva Biologics Enterprise Value: -12.69M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | -12.69M |
| October 31, 2024 | -13.22M |
| October 30, 2024 | -13.20M |
| October 29, 2024 | -13.21M |
| October 28, 2024 | -13.16M |
| October 25, 2024 | -13.15M |
| October 24, 2024 | -13.18M |
| October 23, 2024 | -13.21M |
| October 22, 2024 | -13.23M |
| October 21, 2024 | -13.20M |
| October 18, 2024 | -13.19M |
| October 17, 2024 | -13.23M |
| October 16, 2024 | -13.22M |
| October 15, 2024 | -13.29M |
| October 14, 2024 | -13.30M |
| October 11, 2024 | -13.17M |
| October 10, 2024 | -13.12M |
| October 09, 2024 | -13.03M |
| October 08, 2024 | -13.14M |
| October 07, 2024 | -13.05M |
| October 04, 2024 | -13.00M |
| October 03, 2024 | -12.89M |
| October 02, 2024 | -13.45M |
| October 01, 2024 | -13.41M |
| September 30, 2024 | -13.30M |
| Date | Value |
|---|---|
| September 27, 2024 | -13.19M |
| September 26, 2024 | -12.64M |
| September 25, 2024 | -12.31M |
| September 24, 2024 | -11.41M |
| September 23, 2024 | -11.25M |
| September 20, 2024 | -10.87M |
| September 19, 2024 | -10.88M |
| September 18, 2024 | -10.72M |
| September 17, 2024 | -10.57M |
| September 16, 2024 | -10.82M |
| September 13, 2024 | -10.61M |
| September 12, 2024 | -11.07M |
| September 11, 2024 | -10.78M |
| September 10, 2024 | -10.79M |
| September 09, 2024 | -10.51M |
| September 06, 2024 | -10.30M |
| September 05, 2024 | -11.46M |
| September 04, 2024 | -11.58M |
| September 03, 2024 | -10.56M |
| August 30, 2024 | -8.761M |
| August 29, 2024 | -9.968M |
| August 28, 2024 | -11.17M |
| August 27, 2024 | -11.31M |
| August 26, 2024 | -11.38M |
| August 23, 2024 | -11.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-41.16M
Minimum
Dec 22 2022
125.38M
Maximum
Mar 12 2021
-7.920M
Average
-12.66M
Median
Enterprise Value Benchmarks
| BioCardia Inc | 3.655M |
| NovaBay Pharmaceuticals Inc | 3.615M |
| Palatin Technologies Inc | 13.93M |
| iBio Inc | 9.837M |
| Oragenics Inc | 1.901M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.316M |
| Total Expenses (Quarterly) | 4.42M |
| EPS Diluted (Quarterly) | -10.75 |
| Earnings Yield | -1.57K% |